Fort Washington Investment Advisors Inc. OH cut its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 8.1% during the third quarter, HoldingsChannel.com reports. The firm owned 738,479 shares of the medical instruments supplier’s stock after selling 65,000 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in AngioDynamics were worth $16,055,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Millennium Management LLC acquired a new position in AngioDynamics during the first quarter worth about $3,787,000. Royal Bank of Canada grew its holdings in AngioDynamics by 3.3% during the first quarter. Royal Bank of Canada now owns 126,439 shares of the medical instruments supplier’s stock worth $2,181,000 after acquiring an additional 3,981 shares during the period. Principal Financial Group Inc. grew its holdings in AngioDynamics by 2.7% during the first quarter. Principal Financial Group Inc. now owns 298,168 shares of the medical instruments supplier’s stock worth $5,143,000 after acquiring an additional 7,871 shares during the period. Capital One National Association grew its holdings in AngioDynamics by 68.4% during the second quarter. Capital One National Association now owns 133,551 shares of the medical instruments supplier’s stock worth $2,970,000 after acquiring an additional 54,225 shares during the period. Finally, Boston Advisors LLC acquired a new position in AngioDynamics during the second quarter worth about $1,016,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Shares of ANGO opened at $20.61 on Wednesday. The stock has a market capitalization of $783.27 million, a P/E ratio of 27.85 and a beta of 0.75. AngioDynamics, Inc. has a 1-year low of $15.16 and a 1-year high of $24.49. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.55 and a current ratio of 2.64.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, September 27th. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.02). The company had revenue of $85.34 million during the quarter, compared to analysts’ expectations of $84.05 million. AngioDynamics had a return on equity of 5.44% and a net margin of 4.62%. The company’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.13 EPS. As a group, equities analysts forecast that AngioDynamics, Inc. will post 0.85 EPS for the current year.

In related news, CFO Michael Greiner sold 1,939 shares of AngioDynamics stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $21.53, for a total value of $41,746.67. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 2.80% of the company’s stock.

A number of research analysts recently issued reports on the company. BidaskClub lowered AngioDynamics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 1st. Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 11th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $18.44.

ILLEGAL ACTIVITY WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/11/14/angiodynamics-inc-ango-stake-decreased-by-fort-washington-investment-advisors-inc-oh.html.

AngioDynamics Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Recommended Story: What are the most popular ETFs

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.